Re­call re­port: Nos­trum ex­pands re­call of di­a­betes drug met­formin af­ter car­cino­gen con­cerns

Gener­ic met­formin has been a thorn in drug­mak­ers’ sides for months af­ter a prob­a­ble hu­man car­cino­gen was found in test­ed lots. Now, one of the com­pa­nies is ex­pand­ing its re­call to an­oth­er lot of the drug.

Nos­trum Lab­o­ra­to­ries out of Kansas City, MO vol­un­tar­i­ly re­called one lot of met­formin HCl ex­tend­ed re­lease tablets, USP 750 mg, a type 2 di­a­betes drug (the gener­ic equiv­a­lent to Glu­cophage tablets) af­ter test­ing dis­cov­ered el­e­vat­ed lev­els of ni­trosamine, the prob­a­ble car­cino­gen.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.